Kenneth Mills - Regenxbio CEO
| RGNX Stock | USD 10.00 0.08 0.81% |
CEO
Mr. Kenneth T. Mills is President, Chief Executive Officer, Executive Director of the company. He was our President, Chief Executive Officer and Director since March 2009. Mr. Mills was with FOXKISER, most recently as a Partner, from January 2007 to January 2015. Mr. Mills was previously the Chief Financial Officer and Vice President of Business Development at Meso Scale Diagnostics, a life sciences company, from January 2004 to December 2006 and was part of the original management team that established the companys operations and financing strategy. From March 1997 to December 2003, Mr. Mills was employed at IGEN, a biotechnology company, where he served as Director of Business Development up through the companys acquisition by Roche. Mr. Mills received an S.B. in Chemistry from the Massachusetts Institute of Technology. Mr. Mills qualifications to continue to serve as a member of the Board include his extensive experience as an executive in the gene therapy and biotechnology industries, including as President and Chief Executive Officer of our Company, his prior service as a seniorlevel executive in both early stage and mature biotechnology companies and his demonstrated business judgment. since 2009.
| Age | 49 |
| Tenure | 15 years |
| Address | 9804 Medical Center Drive, Rockville, MD, United States, 20850 |
| Phone | 240 552 8181 |
| Web | https://www.regenxbio.com |
Kenneth Mills Latest Insider Activity
Tracking and analyzing the buying and selling activities of Kenneth Mills against Regenxbio stock is an integral part of due diligence when investing in Regenxbio. Kenneth Mills insider activity provides valuable insight into whether Regenxbio is net buyers or sellers over its current business cycle. Note, Regenxbio insiders must abide by specific rules, including filing SEC forms every time they buy or sell Regenxbio'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Kenneth Mills over three months ago Disposition of 12221 shares by Kenneth Mills of Regenxbio at 3.76 subject to Rule 16b-3 | ||
Kenneth Mills over three months ago Disposition of 2210 shares by Kenneth Mills of Regenxbio at 3.76 subject to Rule 16b-3 | ||
Kenneth Mills over three months ago Disposition of 200 shares by Kenneth Mills of Regenxbio at 3.76 subject to Rule 16b-3 | ||
Kenneth Mills over six months ago Disposition of 15000 shares by Kenneth Mills of Regenxbio at 3.76 subject to Rule 16b-3 |
Regenxbio Management Efficiency
The company has return on total asset (ROA) of (0.2603) % which means that it has lost $0.2603 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.7187) %, meaning that it created substantial loss on money invested by shareholders. Regenxbio's management efficiency ratios could be used to measure how well Regenxbio manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.48 in 2024. Return On Capital Employed is likely to rise to -0.57 in 2024. At this time, Regenxbio's Other Current Assets are fairly stable compared to the past year. Non Currrent Assets Other is likely to rise to about 8.4 M in 2024, whereas Total Assets are likely to drop slightly above 487 M in 2024.Similar Executives
| Found 10 records | CEO Age | ||
| Markus MD | Monte Rosa Therapeutics | 53 | |
| Dinesh Patel | Protagonist Therapeutics | 67 | |
| Scott Struthers | Crinetics Pharmaceuticals | 61 | |
| Sarah Boyce | Avidity Biosciences | 52 | |
| Jeremy MBA | Day One Biopharmaceuticals | 53 | |
| Robert Coffin | Replimune Group | 59 | |
| William MD | Passage Bio | 51 | |
| Matthew CPA | Uniqure NV | 52 | |
| Christopher Peetz | Mirum Pharmaceuticals | 45 | |
| Mark Goldsmith | Revolution Medicines | 62 | |
Management Performance
| Return On Equity | -0.72 | ||||
| Return On Asset | -0.26 |
Regenxbio Leadership Team
Elected by the shareholders, the Regenxbio's board of directors comprises two types of representatives: Regenxbio inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Regenxbio. The board's role is to monitor Regenxbio's management team and ensure that shareholders' interests are well served. Regenxbio's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Regenxbio's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Kenneth Mills, CEO and President Director and Member of Disclosure Committee | ||
| Mitchell MBA, Executive CFO | ||
| Ram PharmD, Executive Operations | ||
| JD II, Executive Officer | ||
| Vittal Vasista, CFO, Sr. VP of Corporate Devel., Treasurer and Member of Disclosure Committee | ||
| Tricia Truehart, VP Communications | ||
| Olivier Danos, Chief Scientific Officer | ||
| Shiva Fritsch, Chief Officer | ||
| Curran MS, Executive COO | ||
| Dr JD, Executive Property | ||
| Andrew Yost, VP Devel | ||
| Stephen MD, Executive Officer |
Regenxbio Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Regenxbio a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.72 | ||||
| Return On Asset | -0.26 | ||||
| Profit Margin | (2.83) % | ||||
| Operating Margin | (2.57) % | ||||
| Current Valuation | 320.09 M | ||||
| Shares Outstanding | 49.55 M | ||||
| Shares Owned By Insiders | 7.39 % | ||||
| Shares Owned By Institutions | 92.25 % | ||||
| Number Of Shares Shorted | 4.62 M | ||||
| Price To Earning | 12.80 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Regenxbio Stock Analysis
When running Regenxbio's price analysis, check to measure Regenxbio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Regenxbio is operating at the current time. Most of Regenxbio's value examination focuses on studying past and present price action to predict the probability of Regenxbio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Regenxbio's price. Additionally, you may evaluate how the addition of Regenxbio to your portfolios can decrease your overall portfolio volatility.